Arovella Therapeutics (ASX:ALA) appointed three "opinion leaders" and clinical oncologists to establish a clinical advisory board to provide strategic advice on CD19-positive hematological malignancies known as blood cancers, according to a Monday filing with the Australian bourse.
The move comes amid the biotech company's plan to file an investigational new drug application with the US Food and Drug Administration and launch its first-in-human phase 1 clinical trial, the filing stated.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.